Prescribe by brand (NACSYS brand) NACSYS 600 mg effervescent tablets is indicated in adults only.
Stop after a 4 week trial if no benefit
Dornase Alfa (Pulmozyme®)
Nebuliser solution 2.5mg/2.5ml
For cystic fibrosis patients only
Hypertonic sodium chloride
Hypertonic Saline 7% Nebules (Nebusal®)
Approved by the HaRD Area Prescribing Committee, January 2015
Non Formulary Items
Mecysteine Hydrochloride (Visclair®)
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
High Cost Medicine
Cancer Drugs Fund
Traffic Light Status Information
Medicines which are suitable to be prescribed in primary care only after specialist recommendation. Ongoing prescribing by primary care includes titration of dose and assessment of efficacy. There is no need for ongoing monitoring other than for general adverse effects as listed in the BNF & SPC.
Medicines which are suitable to be prescribed in primary care only after specialist recommendation only under a shared care protocol once the patient has been stabilised. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must be approved by the Harrogate & Rurual District Area Prescribing Committee (HaRD APC).
Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) has reviewed and does not recommend for use at present based on a review of clinical and/or cost effectiveness data.
Medicines suitable for routine use and can be prescribed within primary care within their licensed indication in accordance with nationally recognised formularies e.g. BNF, BNF for Children, Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.
Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) have not yet reviewed.
Medicines for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician. The drug should be supplied by the hospital for the duration of the treatment course. Primary care prescriber initiation or continuation of treatemnt is not recommended.